ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.
Also NCI prostate SPOREs plan biospecimen bank.
NCI advisors seek comment on clinical trials system, until Jan. 15.
NCI funds 17 EDRN biomarker labs. Bush signs omnibus funding legislation.
Dept. of Defense opens program announcements for prostate cancer research.
Children’s Cancer Research Institute at UT Health Science Center recruits faculty.
Two cancer center directors named: Michael Kastan at St. Jude, James Willson at Harold Simmons.
December issue of Business & Regulatory Report included (an additional 8 pages of industry news).
Next issue of The Cancer Letter is scheduled for Jan. 7, 2005.
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises
New NOFO aims to shrink applications by 40% - California’s Prop 38 is an historic approach to funding medical research, immunology
The $8.4B bond makes a long-term investment in a field with life-saving power - Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Dinah Singer retires from NCI, remains at NIH as Scientist Emeritus
